These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Peptide Receptor Radionuclide Therapy with Cullinane C; Jeffery CM; Roselt PD; van Dam EM; Jackson S; Kuan K; Jackson P; Binns D; van Zuylekom J; Harris MJ; Hicks RJ; Donnelly PS J Nucl Med; 2020 Dec; 61(12):1800-1805. PubMed ID: 32414949 [TBL] [Abstract][Full Text] [Related]
4. Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of Shah RG; Merlin MA; Adant S; Zine-Eddine F; Beauregard JM; Shah GM Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33435224 [TBL] [Abstract][Full Text] [Related]
5. Single-centre experience with peptide receptor radionuclide therapy for neuroendocrine tumours (NETs): results using a theranostic molecular imaging-guided approach. Gordon S; Chan DLH; Bernard EJ; Eslick ME; Willowson KP; Roach PJ; Engel AF; Maher R; Clarke SJ; Agarwal V; Yasmin L; De Silva M; Mascall S; Conner A; Nevell D; Pavlakis N; Bailey DL J Cancer Res Clin Oncol; 2023 Aug; 149(10):7717-7728. PubMed ID: 37004598 [TBL] [Abstract][Full Text] [Related]
6. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models. Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177 [TBL] [Abstract][Full Text] [Related]
7. Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours. Adant S; Shah GM; Beauregard JM Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):907-921. PubMed ID: 31492995 [TBL] [Abstract][Full Text] [Related]
9. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective. Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203 [TBL] [Abstract][Full Text] [Related]
10. Salvage peptide receptor radionuclide therapy with [ van der Zwan WA; Brabander T; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; Krenning EP; de Herder WW Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):704-717. PubMed ID: 30267116 [TBL] [Abstract][Full Text] [Related]
11. Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib. Nonnekens J; van Kranenburg M; Beerens CE; Suker M; Doukas M; van Eijck CH; de Jong M; van Gent DC Theranostics; 2016; 6(11):1821-32. PubMed ID: 27570553 [TBL] [Abstract][Full Text] [Related]
12. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971 [TBL] [Abstract][Full Text] [Related]
13. Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response. Feijtel D; Doeswijk GN; Verkaik NS; Haeck JC; Chicco D; Angotti C; Konijnenberg MW; de Jong M; Nonnekens J Theranostics; 2021; 11(2):491-505. PubMed ID: 33391488 [TBL] [Abstract][Full Text] [Related]
14. Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapy. Evans JS; Beaumont J; Braga M; Masrour N; Mauri F; Beckley A; Butt S; Karali CS; Cawthorne C; Archibald S; Aboagye EO; Sharma R Eur J Cancer; 2022 Nov; 176():110-120. PubMed ID: 36208569 [TBL] [Abstract][Full Text] [Related]
15. Analysis of 177Lu-DOTA-octreotate therapy-induced DNA damage in peripheral blood lymphocytes of patients with neuroendocrine tumors. Denoyer D; Lobachevsky P; Jackson P; Thompson M; Martin OA; Hicks RJ J Nucl Med; 2015 Apr; 56(4):505-11. PubMed ID: 25722453 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of peptide receptor radionuclide therapy (PRRT) in advanced metastatic bronchial neuroendocrine tumours (NETs). Mirvis E; Toumpanakis C; Mandair D; Gnanasegaran G; Caplin M; Navalkissoor S Lung Cancer; 2020 Dec; 150():70-75. PubMed ID: 33075738 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of radiation safety of the newly established national New Zealand 177-Lutetium (177-Lu or Lutate) Peptide Receptor Radiation Therapy (PRRT) service, a palliative treatment for patients with metastatic neuroendocrine tumours. Davidson J; Hull A; Mead T; Lunt B; Stewart A J Med Imaging Radiat Sci; 2022 Jun; 53(2 Suppl):S22-S30. PubMed ID: 35437188 [No Abstract] [Full Text] [Related]
18. Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside. Lewin J; Cullinane C; Akhurst T; Waldeck K; Watkins DN; Rao A; Eu P; Mileshkin L; Hicks RJ Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):25-32. PubMed ID: 25125202 [TBL] [Abstract][Full Text] [Related]
19. Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience. Kesavan M; Turner JH Cancer Biother Radiopharm; 2016 Aug; 31(6):189-98. PubMed ID: 27419665 [TBL] [Abstract][Full Text] [Related]
20. Lutetium-labelled peptides for therapy of neuroendocrine tumours. Kam BL; Teunissen JJ; Krenning EP; de Herder WW; Khan S; van Vliet EI; Kwekkeboom DJ Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1(Suppl 1):S103-12. PubMed ID: 22388631 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]